PRRTInfo.org - A Resource for Patients Considering PRRT Treatment.
PRRTinfo.org is a site for patients considering PRRT (Peptide Receptor Radionuclide Therapy) treatment in Germany written by patients for patients. While much of this information can be used by patients seeking treatment at any PRRT Center worldwide, this site focus is on the treatment as provided by Dr. Richard Baum and his team at the Zentralklinik Bad Berka in Bad Berka, Germany. We also provide links to a select number of other medical centers that offer PRRT which can be found here.
As with any site that offers information on treatment or travel, please confirm medical information with your medical team, as well as any travel information with the travel providers.
We look forward to your feedback.
For the second year in a row, NorCal CarciNET Community and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a patient education day during the SNMMI's Annual Meeting. The program took place on June 8th and began with three (3) general lectures about the definition of nuclear medicine and molecular imaging, safety of nuclear medicine, the value of patient and physician partnerships in care management. The afternoon concluded with breakout sessions focused on hot topics in colon cancer, prostate cancer, thyroid diseases, and neuroendocrine tumors. The total number of attendees was 120 with over 50 attending the NET breakout. To see the complete program and recordings of the breakout sessions, visitwww.snmmi.org/PED. The NET sessions are available below.
Ga-68-labeled somatostatin analogs are important imaging agents to detect and manage neuroendocrine tumors (NETs). The SNMMI formed the 68Ga Users Group to advance the use of these imaging agents in the US. Members of the Users Group developed harmonized release criteria, an imaging manual, generic data collection forms and a draft informed consent form to aid the community in establishing investigator-sponsored trials. In October 2013, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) received orphan drug designation for Ga-68 DOTATOC.
BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Click here to read the full release the Society of Nuclear Medicine and Molecular Imaging and from Josh Mailman, chairman of the Society’s Patient Advocacy Advisory Board and president of the NorCal CarciNET.
A committee of international experts under the auspices of the International Atomic Energy Agency (IAEA), in cooperation with the EANM Therapy, Oncology and Dosimetry Committees and with the Society of Nuclear Medicine and Molecular Imaging, worked together to create this guidance document on the use of somatostatin analogue-based PRRNT. This 120 page guidance document released in February 2013, was compiled taking into account recent literature and experts’ opinion and can be downloaded here. An summary of the guide was also published in the European Journal of Nuclear Medicine and Molecular Imaging.
Over 500 medical professionals attended the 2nd World Congress on Ga68 and Radiotherapy that was held in Chandigarh India, February 28 - March 2, 2013. Over the course of 3 days over 100 presentations and posters were presented reflecting the current usage of Ga68 and PRRT around the world as well as new and exciting development that have taken place since the 1st world congress in 2011. The abstracts for this conference as well as for the 22nd Singapore Nuclear Review are available free of charge at the World Journal of Nuclear Medicine.
This congress saw advancement in using GA68 as a tracer for infection and inflammation as well as for receptor positive forms of breast and prostate cancer in addition to its use as a
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1) is now open in the US and Europe and is actively recruiting patients.
The study is seeking 200 patients at over 50 institutions in a randomized trial - those that are randomized to the non-PRRT arm will receive LAR 60 (high dose).
To learn more about the trial, please visit clinicaltrials.gov.